Establishment Labs Welcomes New CEO

Establishment Labs Holdings Inc. has a new leader.

The company recently made interim CEO Fillipo “Peter” Caldini’s title permanent, officially naming him chief executive. He had served as interim CEO since March 1, when Establishment Labs Founder/former CEO Juan José Chacón-Quirós retired from the position.

“After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs,” Board Chairman Nick Lewin said. “We have a vision and a mission that is very clear, and execution is paramount to ensure that we accomplish all our goals, including turning EBITDA positive in 2025 and cash flow positive in 2026. Our founder, Juan José Chacón-Quirós, continues as a board member and an integral part of the team, from supporting our continued R&D efforts, to ensuring the adoption of our products and technologies by the plastic surgery community. He will advocate around the world for Establishment Labs and its contributions to women’s health.”

Caldini joined Establishment Labs as president last year. Before that, he was CEO and director of Acreage Holdings Inc. from 2020 to 2023 and of Bespoke Capital Acquisition Corp. from 2019 to 2020. Between 2015 and 2019, Caldini worked at Pfizer Consumer Healthcare where he was the regional president for North America and prior to that role, regional president of EMEA. He worked at Bayer Consumer Healthcare from 2009 to 2014, assuming several roles of increasing responsibility, including head of Emerging Markets, general manager of China, and head of the Nutritionals Strategic Business Unit.

Caldini earned his undergraduate degree from Boston University, his MBA from Northeastern University, and a master’s degree in international economics and management from SDA Bocconi.

“It is an honor to be leading Establishment Labs,” Caldini stated. “Our company has transformed breast aesthetics and reconstruction globally though innovation and science, and it is in a unique position to do so again as we launch in the United States. We are building a strong moat in a multibillion-dollar market. Our product suite is one of the most differentiated in medtech, and we are working aggressively to take and expand the market. Most exciting to me is what is in front of us: the chance to marry innovation and best-in-class products with operational excellence so that we can deliver to all our stakeholders, including women, plastic surgeons, and investors.”

Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers solutions for breast health, breast aesthetics, and breast reconstruction in more than 90 countries. With over 4 million Motiva devices delivered to plastic and reconstructive surgeons since 2010, Establishment Labs’ minimally invasive platform consists of Mia Femtech, a unique minimally invasive experience for breast harmonization, and Preservé, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM is a next-generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB (investigational review board) approved pivotal study. The Motiva Flora tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by more than 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820.